HuR inhibition attenuates hypertension and fibrosis in chronic kidney disease

This study demonstrates that pharmacologic inhibition of the RNA-binding protein HuR using the inhibitor KH3 attenuates hypertension, inflammation, oxidative stress, and fibrosis in a mouse model of chronic kidney disease by disrupting a novel HuR-SGLT2 signaling axis, thereby identifying HuR as a promising therapeutic target for hypertensive CKD.

The Gist

The Big Picture: A "Master Switch" Gone Wild

Imagine your body is a bustling city. In this city, Chronic Kidney Disease (CKD) is like a massive, slow-motion traffic jam that eventually shuts down the power plant (the kidneys) and causes the whole city to crumble.

For a long time, doctors have known that high blood pressure (hypertension) is a major cause of this traffic jam. They have tried to fix it by slowing down the traffic lights (using drugs like ACE inhibitors) or removing some cars (diuretics). But often, the jam just gets worse, and the city still falls apart.

This study discovered a new culprit: a tiny protein inside our cells called HuR.

Think of HuR as a hyperactive construction foreman.

• Normally: This foreman helps build necessary repairs when the city is under minor stress.
• In CKD: Something goes wrong, and this foreman goes into a frenzy. He starts shouting orders to build too many walls, too many fences, and too many heavy trucks.
• The Result: The kidneys get clogged with scar tissue (fibrosis), the blood vessels get stiff and tight (causing high blood pressure), and the delicate filters in the kidneys get smashed.

The researchers found that in mice with this "kidney city" in crisis, this foreman (HuR) was working overtime.

The Solution: The "Foreman's Silencer" (KH3)

The scientists developed a special drug called KH3. You can think of KH3 as a noise-canceling headset for the hyperactive foreman. It doesn't kill the foreman; it just stops him from shouting his orders.

When they gave this "silencer" to the sick mice, something amazing happened:

1. The Traffic Jam Cleared: The mice's blood pressure went down.
2. The Scars Faded: The kidneys stopped building unnecessary scar tissue.
3. The Filters Were Saved: The delicate parts of the kidney that clean the blood were protected from damage.

The Secret Connection: The "Sugar Pump" Surprise

Here is the most surprising part of the story.

For years, we knew about a protein called SGLT2. It acts like a sugar pump in the kidneys, reabsorbing sugar. Doctors use drugs to block this pump (SGLT2 inhibitors) to help people with diabetes and kidney disease.

But this study found something new: HuR is the boss of the SGLT2 pump.

• The Analogy: Imagine the SGLT2 pump is a delivery truck. In a healthy city, the truck does its job and goes home. In the sick city, the hyperactive foreman (HuR) keeps ordering more trucks to be built and sent out, even when they aren't needed. These extra trucks clog the roads and cause the blood vessels to squeeze too tight, raising blood pressure.
• The Discovery: When the scientists used the "silencer" (KH3) to stop the foreman, the number of these delivery trucks (SGLT2) dropped. This explains why the blood pressure went down and why the kidneys felt better.

It turns out that HuR isn't just messing with the kidneys; it's also messing with the blood vessels (the roads). It tells the muscle cells in the arteries to squeeze tighter, which spikes blood pressure. By silencing HuR, the roads relaxed, and the pressure dropped.

Why This Matters for You

1. A New Way to Fight Kidney Disease: Current drugs treat the symptoms (like high blood pressure or inflammation) one by one. This study suggests that if we target the "foreman" (HuR), we can stop the whole chain reaction at the source. It's like fixing the root cause of the traffic jam rather than just directing cars around it.
2. Explaining Old Drugs: This research helps explain why SGLT2 inhibitors (a popular class of kidney drugs) work so well, even in people who don't have diabetes. It's because they are indirectly calming down the stress signals that HuR was amplifying.
3. A Two-for-One Deal: Because HuR controls both the kidneys and the blood vessels, a drug that targets it could potentially lower blood pressure and save the kidneys at the same time.

The Bottom Line

The researchers found that a specific protein (HuR) acts like a broken alarm system in kidney disease, screaming "Build! Squeeze! Scar!" when it should be quiet. By using a new drug (KH3) to silence this alarm, they were able to stop the damage, lower blood pressure, and protect the kidneys in their animal models.

It's a promising new direction that could lead to better treatments for the millions of people struggling with kidney disease and high blood pressure.

Technical Summary

1. Problem Statement

Chronic Kidney Disease (CKD) remains a major global health burden with limited therapeutic options to halt progression to End-Stage Kidney Disease (ESKD). While current therapies (ACE inhibitors, ARBs, SGLT2 inhibitors) slow progression, they often fail to fully control hypertension or reverse renal fibrosis and vascular dysfunction.

• The Gap: The upstream molecular regulators that integrate renal injury, vascular dysfunction, and blood pressure control in hypertensive CKD are incompletely defined.
• The Hypothesis: The RNA-binding protein HuR (ELAVL1), known to stabilize inflammatory and fibrotic mRNAs, is upregulated in CKD and acts as a central driver of disease progression. Furthermore, its inhibition might offer a novel therapeutic strategy to lower blood pressure and reduce fibrosis, potentially via a newly discovered link to SGLT2 expression in vascular cells.

2. Methodology

The study employed a multi-modal approach combining in vivo animal models, ex vivo vascular reactivity assays, and in vitro cell culture experiments.

• Animal Model:

  • Subjects: Adult male C57BL/6 mice.
  • Induction: Uninephrectomy followed by DOCA (deoxycorticosterone acetate) + Angiotensin II (Ang II) infusion for 3 weeks to induce hypertensive CKD.
  • Intervention: Mice were treated with the small-molecule HuR inhibitor KH3 (40 mg/kg/day, i.p.) or vehicle.
  • Controls: Normal saline-injected mice.
  • Measurements: Systolic blood pressure (tail-cuff), body weight, water intake, urine output, albuminuria (ACR/UAE), and renal function (BUN/Cr).

• Molecular & Histological Analysis:

  • Tissue: Kidney cortex, aortas, and circulating plasma exosomes.
  • Techniques: Western blotting, RT-qPCR, Immunofluorescence (IF), and Immunohistochemistry (IHC).
  • Targets: HuR localization, fibrotic markers (TGF-β1, Wisp1, α-SMA, Collagen III), inflammatory markers (NF-κB, Nox2, macrophages), podocyte integrity (nephrin/podocin), and sodium transporters (SGLT2, ENaC).

• Cellular & Vascular Studies:

  • Cell Lines: Primary mouse vascular smooth muscle cells (mVSMCs) and proximal tubular cells (mPTCs).
  • Stimuli: TGF-β1 and Ang II to induce stress responses.
  • Vascular Reactivity: Ex vivo isometric tension studies on mesenteric resistance arteries to assess vasoconstriction (Ang II, KCl, Phenylephrine) and relaxation (ACh, SNP) in the presence of KH3, dapagliflozin (SGLT2 inhibitor), or both.

3. Key Contributions

1. Identification of HuR as a Systemic Regulator: Demonstrated that HuR is upregulated not only in renal tissue but also in circulating exosomes in hypertensive CKD, serving as a systemic biomarker and driver.
2. Discovery of a Novel HuR-SGLT2-VSMC Axis: Uncovered that HuR regulates SGLT2 expression in vascular smooth muscle cells (VSMCs), a finding previously unrecognized as SGLT2 is traditionally viewed as a renal transporter.
3. Mechanism of Antihypertensive Action: Provided the first evidence that pharmacologic inhibition of HuR lowers arterial blood pressure in vivo, distinct from its renal protective effects.
4. Additive Therapeutic Potential: Showed that HuR inhibition and SGLT2 inhibition (dapagliflozin) have additive effects in blunting Ang II-mediated vasoconstriction.

4. Key Results

A. HuR Upregulation and KH3 Efficacy

• Expression: DOCA + Ang II infusion significantly increased HuR levels in kidney tissue (glomerular, tubular, vascular) and circulating exosomes.
• Inhibition: KH3 treatment effectively reduced HuR levels in both compartments.
• Clinical Outcomes: KH3 treatment:
  • Lowered Blood Pressure: Partially but significantly attenuated hypertension.
  • Improved Renal Function: Reduced BUN and Creatinine.
  • Reduced Albuminuria: Significantly lowered urinary albumin excretion and ACR.
  • Attenuated Fibrosis: Reduced kidney hypertrophy, glomerular extracellular matrix expansion, and tubulointerstitial fibrosis (collagen deposition).

B. Cellular Protection

• Podocytes: KH3 preserved the expression of nephrin and podocin, maintaining slit diaphragm integrity.
• Tubules: Markedly reduced injury markers (Kim-1, NGAL, OPN).
• Inflammation/Oxidative Stress: Suppressed NF-κBp65, Nox2, AKT phosphorylation, and macrophage (F4/80) infiltration.

C. The HuR-SGLT2-VSMC Mechanism

• Renal SGLT2: DOCA + Ang II increased SGLT2 in renal tubules and vessels; KH3 reduced this expression.
• Vascular SGLT2: SGLT2 was detected in VSMCs and upregulated by TGF-β1/Ang II.
• Mechanistic Link: TGF-β1 induced cytoplasmic translocation of HuR in VSMCs, leading to increased SGLT2 mRNA/protein. KH3 blocked this translocation and subsequent SGLT2 upregulation.
• Vascular Reactivity:
  • Ang II-induced vasoconstriction was blunted by KH3.
  • Dapagliflozin (SGLT2 inhibitor) also blunted vasoconstriction.
  • Combination: KH3 + Dapagliflozin showed additive effects in reducing Ang II-mediated vasoconstriction without affecting endothelial function.

D. Sodium Handling Specificity

• KH3 reduced SGLT2 expression but had minimal effect on ENaC subunits (except a modest reduction in ENaC-α), suggesting the antihypertensive effect is mediated primarily through SGLT2-associated pathways and vascular remodeling rather than global ENaC suppression.

5. Significance and Clinical Implications

• Novel Therapeutic Target: HuR inhibition represents a mechanism-based strategy to target the upstream drivers of CKD progression, addressing inflammation, fibrosis, and hypertension simultaneously.
• Reconciling Genetic Discrepancies: The study clarifies why HuR deletion causes hypertension in some genetic models (developmental defects) while HuR inhibition in adult disease lowers blood pressure (targeting maladaptive overactivation).
• Explaining SGLT2 Benefits: The findings provide a mechanistic explanation for the cardiovascular benefits of SGLT2 inhibitors in non-diabetic CKD. It suggests that SGLT2 inhibitors may work partly by interrupting a HuR-driven pro-fibrotic and pro-constrictive signaling loop in the vasculature.
• Future Directions: The study supports the development of HuR inhibitors as a complementary therapy to RAAS blockade and SGLT2 inhibitors, potentially offering superior control of blood pressure and vascular protection in hypertensive CKD.

Conclusion:
The study establishes HuR as a central post-transcriptional regulator linking renal injury and vascular dysfunction in CKD. Pharmacologic inhibition of HuR (via KH3) attenuates hypertension and fibrosis by suppressing a novel HuR-SGLT2 signaling axis in vascular smooth muscle cells, offering a promising new avenue for treating hypertensive kidney disease.